NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 58.19

+0.3%

11:52 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david nordic who wrote (314)	6/9/2010 9:38:07 AM
From: Arthur Radley	of 507

Positive data out today on breast cancer, and Cantor was paying attention to ASCO data for ovarian cancer... Cantor Fitzgerald Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Proven Technology Fuels New Growth 7:42 am ET 06/09/2010 - StreetInsider Cantor Fitzgerald initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with a Buy rating. PT $21. Cantor analyst says, "We consider NKTR substantially under valued and consider the anticipated NKTR-102 pharma partnership a significant catalyst for the stock. Single-agent NKTR-102 demonstrated significant anti-tumor activity based on Gynecologic Cancer InterGroup (GCIG) criteria with a tolerable safety profile. We expect additional positive Phase II data in metastatic ovarian and breast cancers, enhancing partnership potential and deal term attractiveness." To see all the upgrades/downgrades on shares of NKTR, visit our Analyst Ratings page. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next